Peringatan Keamanan

Symptoms of a methscopolamine overdose include headache, nausea, vomiting, dry mouth, difficulty swallowing, blurred vision, dilated pupils, hot, dry skin, dizziness; drowsiness, confusion, anxiety, seizures, weak pulse, and an irregular heartbeat. In addition, a curare-like action may occur, i.e., neuromuscular blockade leading to muscular weakness and possible paralysis.

Methscopolamine bromide

DB00462

small molecule approved

Deskripsi

A muscarinic antagonist used to study binding characteristics of muscarinic cholinergic receptors.

Struktur Molekul 2D

Berat 398.297
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Poorly and unreliably absorbed, total absorption is 10-25%.

Metabolisme

Little is known about the fate and excretion of methscopolamine.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Makanan

1 Data
  • 1. Take before a meal. Take methscopolamine bromide 30 minutes before meals and at bedtime for optimal therapeutic effect.

Interaksi Obat

516 Data
Aclidinium The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Aclidinium.
Mianserin Mianserin may increase the anticholinergic activities of Methscopolamine bromide.
Mirabegron The risk or severity of urinary retention can be increased when Methscopolamine bromide is combined with Mirabegron.
Potassium chloride The risk or severity of gastrointestinal ulceration can be increased when Methscopolamine bromide is combined with Potassium chloride.
Pramlintide The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Methscopolamine bromide.
Secretin porcine The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Methscopolamine bromide.
Tiotropium The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Tiotropium.
Topiramate The risk or severity of hyperthermia and oligohydrosis can be increased when Methscopolamine bromide is combined with Topiramate.
Umeclidinium The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Umeclidinium.
Glycopyrronium The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Glycopyrronium.
Botulinum toxin type A The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Botulinum toxin type A.
Glucagon Methscopolamine bromide may increase the gastrointestinal motility reducing activities of Glucagon.
Sulpiride Methscopolamine bromide may increase the anticholinergic activities of Sulpiride.
Botulinum toxin type B The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Botulinum toxin type B.
Eluxadoline The risk or severity of constipation can be increased when Methscopolamine bromide is combined with Eluxadoline.
Ramosetron The risk or severity of constipation can be increased when Methscopolamine bromide is combined with Ramosetron.
Naltrexone The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Naltrexone.
Bezitramide The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Bezitramide.
Tramadol The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Tramadol.
Morphine The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Morphine.
Codeine The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Codeine.
Hydromorphone The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Hydromorphone.
Methadone The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Methadone.
Meperidine The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Meperidine.
Oxycodone The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Oxycodone.
Butorphanol The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Butorphanol.
Dextropropoxyphene The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Dextropropoxyphene.
Pentazocine The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Pentazocine.
Sufentanil The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Sufentanil.
Alfentanil The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Alfentanil.
Fentanyl The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Fentanyl.
Nalbuphine The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Nalbuphine.
Levorphanol The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Levorphanol.
Remifentanil The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Remifentanil.
Buprenorphine The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Buprenorphine.
Hydrocodone The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Hydrocodone.
Diphenoxylate The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Diphenoxylate.
Oxymorphone The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Oxymorphone.
Dezocine The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Dezocine.
Levacetylmethadol The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Levacetylmethadol.
Methadyl acetate The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Methadyl acetate.
Dihydroetorphine The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Dihydroetorphine.
Diamorphine The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Diamorphine.
Ethylmorphine The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Ethylmorphine.
Etorphine The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Etorphine.
Dextromoramide The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Dextromoramide.
Desomorphine The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Desomorphine.
Carfentanil The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Carfentanil.
Dihydrocodeine The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Dihydrocodeine.
Alphacetylmethadol The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Alphacetylmethadol.
Dihydromorphine The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Dihydromorphine.
Tapentadol The risk or severity of urinary retention and constipation can be increased when Methscopolamine bromide is combined with Tapentadol.
Ketobemidone The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Ketobemidone.
DPDPE The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with DPDPE.
Lofentanil The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Lofentanil.
Opium The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Opium.
Normethadone The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Normethadone.
Piritramide The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Piritramide.
Alphaprodine The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Alphaprodine.
Nicomorphine The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Nicomorphine.
Meptazinol The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Meptazinol.
Phenoperidine The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Phenoperidine.
Phenazocine The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Phenazocine.
Tilidine The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Tilidine.
Carfentanil, C-11 The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Carfentanil, C-11.
Benzhydrocodone The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Benzhydrocodone.
Naloxegol The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Naloxegol.
Trospium The risk or severity of adverse effects can be increased when Trospium is combined with Methscopolamine bromide.
Oxyphenonium The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Methscopolamine bromide.
Benzatropine The risk or severity of adverse effects can be increased when Benzatropine is combined with Methscopolamine bromide.
Disopyramide The risk or severity of adverse effects can be increased when Disopyramide is combined with Methscopolamine bromide.
Metixene The risk or severity of adverse effects can be increased when Metixene is combined with Methscopolamine bromide.
Terfenadine The risk or severity of adverse effects can be increased when Terfenadine is combined with Methscopolamine bromide.
Buclizine The risk or severity of adverse effects can be increased when Buclizine is combined with Methscopolamine bromide.
Trihexyphenidyl The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Methscopolamine bromide.
Oxyphencyclimine The risk or severity of adverse effects can be increased when Oxyphencyclimine is combined with Methscopolamine bromide.
Procyclidine The risk or severity of adverse effects can be increased when Procyclidine is combined with Methscopolamine bromide.
Hyoscyamine The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Methscopolamine bromide.
Darifenacin The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Darifenacin.
Tridihexethyl The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Tridihexethyl.
Anisotropine methylbromide The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Anisotropine methylbromide.
Atropine The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Atropine.
Nicardipine The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Nicardipine.
Mecamylamine The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Mecamylamine.
Pirenzepine The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Pirenzepine.
Homatropine methylbromide The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Homatropine methylbromide.
Benzquinamide The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Benzquinamide.
Propantheline The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Propantheline.
Dicyclomine The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Dicyclomine.
Tropicamide The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Tropicamide.
Cocaine The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Cocaine.
Quinidine The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Quinidine.
Amantadine The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Amantadine.
Methantheline The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Methantheline.
Cycrimine The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Cycrimine.
Cyclopentolate The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Cyclopentolate.
Tolterodine The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Tolterodine.
Oxybutynin The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Oxybutynin.
Pentolinium The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Pentolinium.
Trimethaphan The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Trimethaphan.

Target Protein

Muscarinic acetylcholine receptor M2 CHRM2
Muscarinic acetylcholine receptor M1 CHRM1
Muscarinic acetylcholine receptor M3 CHRM3

Referensi & Sumber

Belum ada data referensi/link/attachment untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field referensi.

Contoh Produk & Brand

Produk: 21 • International brands: 1
Produk
  • Methscopolamine
    Tablet • 5 mg/1 • Oral • US • Generic • Approved
  • Methscopolamine Bromide
    Tablet • 2.5 mg/1 • Oral • US • Generic • Approved
  • Methscopolamine Bromide
    Tablet • 5 mg/1 • Oral • US • Generic • Approved
  • Methscopolamine Bromide
    Tablet • 2.5 mg/1 • Oral • US • Approved
  • Methscopolamine Bromide
    Tablet • 5 mg/1 • Oral • US • Approved
  • Methscopolamine Bromide
    Tablet • 2.5 mg/1 • Oral • US • Generic • Approved
  • Methscopolamine Bromide
    Tablet • 5 mg/1 • Oral • US • Generic • Approved
  • Methscopolamine Bromide
    Tablet • 2.5 mg/1 • Oral • US • Generic • Approved
Menampilkan 8 dari 21 produk.
International Brands
  • Pamine

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul